The Association Between Glycaemic Variability and Progression of Chronic Kidney Disease: a Systematic Review

Hellena Habte-Asres; David Wheeler; Angus Forbes

doi:10.1007/s42399-022-01182-5

The Association Between Glycaemic Variability and Progression of Chronic Kidney Disease: a Systematic Review

Hellena Habte-Asres, David Wheeler, Angus Forbes

Care in Long Term Conditions

UCL University College London

Research output: Contribution to journal › Article › peer-review

Abstract

The study aims to evaluate the association between glycaemic variability and the risk of chronic kidney disease (CKD) progression in patients with diabetes and comorbid kidney disease. A comprehensive search was conducted of three databases from their inception to March 2022: Medline, Embase, and CINHAL. Publications were screened for eligibility and the quality of studies included was appraised using the Newcastle–Ottawa Scale. Extracted data were tabulated and reported in a narrative synthesis. Fourteen studies were included in the review providing data on 62,498 participants. Eight studies reported that greater glycaemic variability was associated with an increased incidence of CKD. Three studies reported an increased likelihood of CKD progression in those with high glycaemic variability, although the rate and risk of progression varied across the studies. Three studies reported an increased risk of progression to end-stage kidney disease (ESKD) with higher glycaemic variability. One study found that high glycaemic variability was associated with a decreased risk of progression to ESKD. Greater glycaemic variability was associated with the onset and progression of CKD. More research is required to verify whether glycaemic variability increases the risk of progression to ESKD in patients with diabetes and mild/moderate comorbid CKD.

Original language	English
Journal	SN Comprehensive Clinical Medicine
DOIs	https://doi.org/10.1007/s42399-022-01182-5
Publication status	Published - 22 Apr 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s42399-022-01182-5

Cite this

@article{5a1a6609ce804af987b877d914e73a10,

title = "The Association Between Glycaemic Variability and Progression of Chronic Kidney Disease: a Systematic Review",

abstract = "The study aims to evaluate the association between glycaemic variability and the risk of chronic kidney disease (CKD) progression in patients with diabetes and comorbid kidney disease. A comprehensive search was conducted of three databases from their inception to March 2022: Medline, Embase, and CINHAL. Publications were screened for eligibility and the quality of studies included was appraised using the Newcastle–Ottawa Scale. Extracted data were tabulated and reported in a narrative synthesis. Fourteen studies were included in the review providing data on 62,498 participants. Eight studies reported that greater glycaemic variability was associated with an increased incidence of CKD. Three studies reported an increased likelihood of CKD progression in those with high glycaemic variability, although the rate and risk of progression varied across the studies. Three studies reported an increased risk of progression to end-stage kidney disease (ESKD) with higher glycaemic variability. One study found that high glycaemic variability was associated with a decreased risk of progression to ESKD. Greater glycaemic variability was associated with the onset and progression of CKD. More research is required to verify whether glycaemic variability increases the risk of progression to ESKD in patients with diabetes and mild/moderate comorbid CKD.",

author = "Hellena Habte-Asres and David Wheeler and Angus Forbes",

year = "2022",

month = apr,

day = "22",

doi = "10.1007/s42399-022-01182-5",

language = "English",

journal = "SN Comprehensive Clinical Medicine",

}

TY - JOUR

T1 - The Association Between Glycaemic Variability and Progression of Chronic Kidney Disease: a Systematic Review

AU - Habte-Asres, Hellena

AU - Wheeler, David

AU - Forbes, Angus

PY - 2022/4/22

Y1 - 2022/4/22

N2 - The study aims to evaluate the association between glycaemic variability and the risk of chronic kidney disease (CKD) progression in patients with diabetes and comorbid kidney disease. A comprehensive search was conducted of three databases from their inception to March 2022: Medline, Embase, and CINHAL. Publications were screened for eligibility and the quality of studies included was appraised using the Newcastle–Ottawa Scale. Extracted data were tabulated and reported in a narrative synthesis. Fourteen studies were included in the review providing data on 62,498 participants. Eight studies reported that greater glycaemic variability was associated with an increased incidence of CKD. Three studies reported an increased likelihood of CKD progression in those with high glycaemic variability, although the rate and risk of progression varied across the studies. Three studies reported an increased risk of progression to end-stage kidney disease (ESKD) with higher glycaemic variability. One study found that high glycaemic variability was associated with a decreased risk of progression to ESKD. Greater glycaemic variability was associated with the onset and progression of CKD. More research is required to verify whether glycaemic variability increases the risk of progression to ESKD in patients with diabetes and mild/moderate comorbid CKD.

AB - The study aims to evaluate the association between glycaemic variability and the risk of chronic kidney disease (CKD) progression in patients with diabetes and comorbid kidney disease. A comprehensive search was conducted of three databases from their inception to March 2022: Medline, Embase, and CINHAL. Publications were screened for eligibility and the quality of studies included was appraised using the Newcastle–Ottawa Scale. Extracted data were tabulated and reported in a narrative synthesis. Fourteen studies were included in the review providing data on 62,498 participants. Eight studies reported that greater glycaemic variability was associated with an increased incidence of CKD. Three studies reported an increased likelihood of CKD progression in those with high glycaemic variability, although the rate and risk of progression varied across the studies. Three studies reported an increased risk of progression to end-stage kidney disease (ESKD) with higher glycaemic variability. One study found that high glycaemic variability was associated with a decreased risk of progression to ESKD. Greater glycaemic variability was associated with the onset and progression of CKD. More research is required to verify whether glycaemic variability increases the risk of progression to ESKD in patients with diabetes and mild/moderate comorbid CKD.

U2 - 10.1007/s42399-022-01182-5

DO - 10.1007/s42399-022-01182-5

M3 - Article

JO - SN Comprehensive Clinical Medicine

JF - SN Comprehensive Clinical Medicine

ER -